On Tuesday, jurors listened to opening statements in a class-action lawsuit focused on an alleged conspiracy to increase prices and limit competition for medications utilized in the treatment of HIV.
The drug company case was the focus of Tuesday’s court proceedings, with arguments from all parties involved. The trial will continue until the end of June, with US District Judge Edward Chen presiding over the case.
A group of customers, including health funds and workers’ unions, filed a lawsuit in 2019 against Gilead Sciences in a federal court in California. The lawsuit alleged that the pharmaceutical company engaged in a “long-running scheme” to limit competition for antiretroviral therapy medications used to treat HIV.
Related: US: Gilead hit with antitrust suit over price-fixing HIV drugs
The lawsuit against Gilead alleges anticompetitive and anti-consumer behavior, such as highly-priced HIV drugs and hindering the entrance of generic drugs into the market. As a result, the lawsuit claims that Gilead has maintained a monopoly in the market for modern HIV treatment drugs.
The lawsuit centers around whether Gilead Sciences made an agreement with Teva, an Israeli generic pharmaceuticals company, to delay the introduction of generic drugs to the market. Gilead, headquartered in Foster City, California, had revenue of over $28 billion in 2022, while Teva’s revenue in 2021 was over $16 billion.
Featured News
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Turkey Hits Meta with $37.20 Million Fine Over Data-Sharing Practices
May 8, 2024 by
CPI
Google Seeks Dismissal of UK Suit Over Alleged Anti-Competitive Practices
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI